Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
IGA NephropathyProteinuria
Interventions
BIOLOGICAL

OPL-CCL2-LPM

"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"

Trial Locations (3)

A1B 3V6

Eastern Health, HSC, Memorial University, St. John's

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

H1T 2M4

Hoptial Maisonneuve-Rosemont, Montreal

All Listed Sponsors
lead

Osprey Pharmaceuticals USA, Inc.

INDUSTRY